Therefore, given the regulatory role in the inhibition of tumorigenesis-related signaling pathways, we assumed that PBLD might represent a promising therapeutic target for cancer progression mainly via ERK1/2 pathways and VEGF-A. This evidence concerns the gene MAPK3 and cancer.